Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavß in patients with advanced solid tumours

Ferry Eskens; H Dumez; R (Rosa) Hoekstra; A Perschl; CJ Brindley; S Böttcher; W Wynendaele; J Drevs; Jaap Verweij; AT van Oosterom

doi:10.1016/S0959-8049(03)00057-1

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavß in patients with advanced solid tumours

Ferry Eskens, H Dumez, R (Rosa) Hoekstra, A Perschl, CJ Brindley, S Böttcher, W Wynendaele, J Drevs, Jaap Verweij, AT van Oosterom

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

219 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	917-926
Number of pages	10
Journal	European Journal of Cancer
Volume	39
DOIs	https://doi.org/10.1016/S0959-8049(03)00057-1
Publication status	Published - 2003

Research programs

EMC MM-03-86-08

Access to Document

10.1016/S0959-8049(03)00057-1

http://hdl.handle.net/1765/63567

Cite this

Eskens, F., Dumez, H., Hoekstra, R., Perschl, A., Brindley, CJ., Böttcher, S., Wynendaele, W., Drevs, J., Verweij, J., & van Oosterom, AT. (2003). Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavß in patients with advanced solid tumours. European Journal of Cancer, 39, 917-926. https://doi.org/10.1016/S0959-8049(03)00057-1

@article{2f147bb052ec4fed85d091d4670bc7c0,

title = "Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphav{\ss} in patients with advanced solid tumours",

author = "Ferry Eskens and H Dumez and Hoekstra, {R (Rosa)} and A Perschl and CJ Brindley and S B{\"o}ttcher and W Wynendaele and J Drevs and Jaap Verweij and {van Oosterom}, AT",

year = "2003",

doi = "10.1016/S0959-8049(03)00057-1",

language = "Undefined/Unknown",

volume = "39",

pages = "917--926",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Eskens, F, Dumez, H, Hoekstra, R, Perschl, A, Brindley, CJ, Böttcher, S, Wynendaele, W, Drevs, J, Verweij, J & van Oosterom, AT 2003, 'Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavß in patients with advanced solid tumours', European Journal of Cancer, vol. 39, pp. 917-926. https://doi.org/10.1016/S0959-8049(03)00057-1

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavß in patients with advanced solid tumours. / Eskens, Ferry; Dumez, H; Hoekstra, R (Rosa) et al.
In: European Journal of Cancer, Vol. 39, 2003, p. 917-926.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavß in patients with advanced solid tumours

AU - Eskens, Ferry

AU - Dumez, H

AU - Hoekstra, R (Rosa)

AU - Perschl, A

AU - Brindley, CJ

AU - Böttcher, S

AU - Wynendaele, W

AU - Drevs, J

AU - Verweij, Jaap

AU - van Oosterom, AT

PY - 2003

Y1 - 2003

U2 - 10.1016/S0959-8049(03)00057-1

DO - 10.1016/S0959-8049(03)00057-1

M3 - Article

SN - 0959-8049

VL - 39

SP - 917

EP - 926

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -